Get the Stockscreener App
10.14
0.20%
0.02
After Hours:
10.18
0.04
+0.39%
Iteos Therapeutics Inc stock is traded at $10.14, with a volume of 962.74K.
It is up +0.20% in the last 24 hours and up +1.71% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.12
Open:
$10.12
24h Volume:
962.74K
Relative Volume:
0.61
Market Cap:
$388.10M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.219
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
-0.10%
1M Performance:
+1.71%
6M Performance:
+34.48%
1Y Performance:
-42.35%
1-Day Range:
$10.11
$10.16
1-Week Range:
$10.10
$10.20
52-Week Range:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.14 | 447.01M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionTrade Timing Strategy With Technical Data Explained - metal.it
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Visual trend scoring systems applied to iTeos Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
What catalysts could drive iTeos Therapeutics Inc. stock higher in 2025Wealth Building Planner With Proven Results - jammulinksnews.com
These 10 Stocks are Winning Big - Insider Monkey
What makes iTeos Therapeutics Inc. stock price move sharplyTrade Timing Strategy With Technical Data Explained - metal.it
iTeos Therapeutics Inc. Added to High Probability Setup ListTriple Return Setup With Risk Control Explained - metal.it
Is iTeos Therapeutics Inc. stock overvalued or undervaluedSuperior returns - jammulinksnews.com
Price momentum metrics for iTeos Therapeutics Inc. explainedWeekly Stock Movement Prediction Watchlist - Newser
Is iTeos Therapeutics Inc. stock poised for growthReliable Investment Entry Signals Confirmed by Charts - metal.it
Using data tools to time your iTeos Therapeutics Inc. exitFree Early Entry Picks Before News Breakout - Newser
Can momentum traders help lift iTeos Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Price momentum metrics for iTeos Therapeutics Inc. explained Long-Term Safety Investment Analysis Report - Newser
What is iTeos Therapeutics Inc. company’s growth strategyExponential return rates - jammulinksnews.com
How strong is iTeos Therapeutics Inc. company’s balance sheetInvest smarter with expert trading signals - jammulinksnews.com
What is the dividend policy of iTeos Therapeutics Inc. stockMaximize gains with timely market signals - jammulinksnews.com
How volatile is iTeos Therapeutics Inc. stock compared to the marketNavigate market shifts with confidence - jammulinksnews.com
Is iTeos Therapeutics Inc. a growth stock or a value stockGet timely alerts on market opportunities - jammulinksnews.com
How Efficient Is iTeos Therapeutics Inc. at Controlling Operating CostsFree Deep Market Trend Analysis - Newser
Key External Factors That Drive iTeos Therapeutics Inc. Stock Price MovementsDaily Breakout Picks - Newser
Will iTeos Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsCapital Growth Picks - Newser
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Selection with 300% Return - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders - GlobeNewswire Inc.
Wedbush Research Analysts Cut Earnings Estimates for ITOS - Defense World
iTeos Therapeutics Inc. Stock Analysis and ForecastRecord-breaking capital gains - PrintWeekIndia
Will iTeos Therapeutics Inc. stock split in the near futureHigh-yield investments - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceExceptional growth trajectory - PrintWeekIndia
Q2 EPS Estimate for iTeos Therapeutics Lowered by Analyst - Defense World
SHAREHOLDER ALERT: Morris Kandinov Investigating AVDX, - GlobeNewswire
What analysts say about iTeos Therapeutics Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
Is iTeos Therapeutics Inc. stock overhyped or has real potentialFree Predictions - jammulinksnews.com
Assessing the Fairness of iTeos Therapeutics' $10.047-per-Share Acquisition Offer: A Valuation Deep Dive - AInvest
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc.ITOS - The Globe and Mail
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter
Concentra buys beleaguered iTeos at slight discount - PharmaLive
iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com Canada
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):